<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">docru</journal-id><journal-title-group><journal-title xml:lang="ru">Доктор.Ру</journal-title><trans-title-group xml:lang="en"><trans-title>Title</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1727-2378</issn><issn pub-type="epub">2713-2994</issn><publisher><publisher-name>ООО "ГК "РУСМЕДИКАЛ"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31550/1727-2378-2022-21-8-18-24</article-id><article-id custom-type="elpub" pub-id-type="custom">docru-28</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕВРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEUROLOGY</subject></subj-group></article-categories><title-group><article-title>Закономерности формирования и оценка эффективности терапии лекарственно-индуцированной головной боли</article-title><trans-title-group xml:lang="en"><trans-title>Patterns of Formation and Evaluation of the Efficiency of Medical Overuse Headache Therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7698-725X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гузий</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Guziy</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гузий Елена Александровна — аспирант кафедры нервных болезней и нейрохирургии Института клинической медицины имени Н.В. Склифосовского</p><p>119021, г. Москва, ул. Россолимо, д. 11, стр. 1</p></bio><bio xml:lang="en"><p>1 Rossolimo Str., build. 1, Moscow, 119021</p></bio><email xlink:type="simple">ena15637@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2561-5944</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шагбазян</surname><given-names>А. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Shagbazyan</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шагбазян Анаит Эдуардовна — врач-невролог клиники</p><p>111394, г. Москва, ул. Перовская, д. 66, кор. 3</p></bio><bio xml:lang="en"><p>66 Perovskaya Str., build. 3, Moscow, 111394</p></bio><email xlink:type="simple">sha-a_89@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8437-7205</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковальчук</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovalchuk</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ковальчук Надежда Александровна — аспирант кафедры нервных болезней и нейрохирургии Института клинической медицины имени Н.В. Склифосовского</p><p>119021,  г. Москва, ул. Россолимо, д. 11, стр. 1</p></bio><bio xml:lang="en"><p>1 Rossolimo Str., build. 1, Moscow, 119021</p></bio><email xlink:type="simple">dr.N.Kovalchuk@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3833-532X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Табеева</surname><given-names>Г. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Tabeeva</surname><given-names>G. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Табеева Гюзяль Рафкатовна — профессор кафедры нервных болезней и нейрохирургии Института клинической медицины имени Н.В. Склифосовского</p><p>119021, г. Москва, ул. Россолимо, д. 11, стр. 1</p></bio><bio xml:lang="en"><p>1 Rossolimo Str., build. 1, Moscow, 119021</p></bio><email xlink:type="simple">grtabeeva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ООО «Правильное лечение»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>LLC Right Treatment</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>13</day><month>02</month><year>2025</year></pub-date><volume>21</volume><issue>8</issue><issue-title>НЕВРОЛОГИЯ. ПСИХИАТРИЯ</issue-title><fpage>18</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гузий Е.А., Шагбазян А.Э., Ковальчук Н.А., Табеева Г.Р., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Гузий Е.А., Шагбазян А.Э., Ковальчук Н.А., Табеева Г.Р.</copyright-holder><copyright-holder xml:lang="en">Guziy E.A., Shagbazyan A.E., Kovalchuk N.A., Tabeeva G.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://docru.elpub.ru/jour/article/view/28">https://docru.elpub.ru/jour/article/view/28</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: оценить закономерности формирования лекарственно-индуцированной головной боли (ЛИГБ), эффективность терапии, а также сравнить две группы пациентов с хронической мигренью и злоупотреблением симптоматическими средствами: с ЛИГБ и без нее.</p></sec><sec><title>Дизайн</title><p>Дизайн: проспективное когортное исследование.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включены 20 пациентов от 18 до 75 лет с установленным диагнозом хронической мигрени и чертами злоупотребления симптоматическими средствами. У всех больных подробно проанализированы жалобы, анамнез заболевания, социо-демографический и клинико-психологический статус, характеристики боли до и во время лечения, влияние головной боли на повседневную активность.</p></sec><sec><title>Результаты</title><p>Результаты. Всем пациентам были рекомендованы отмена «виновного» анальгетика и ограничение приема препарата с обезболивающим действием из другой группы. Для профилактики использовались метопролол в 6 (30%) случаях, топирамат — в 2 (10%), амитриптилин — в 30%, венлафаксин — в 30%. Спустя 3 месяца от начала терапии наибольшее снижение частоты и интенсивности головной боли отметили пациенты при приеме амитриптилина в дозе до 50 мг, венлафаксина в дозе до 150 мг. В момент отмены «рикошетные» симптомы и синдром отмены развились у 14 (70%) человек. Детоксикационная терапия (дексаметазон 4–8 мг на 200 мл физраствора и магнезия 10% 25 мл № 10) проводилась у 12 (60%) больных. За 3 месяца наблюдения интенсивность приступа головной боли снизилась на 2 балла по визуальной аналоговой шкале, а продолжительность — в среднем на 6 часов, количество дней с головной болью уменьшилось в среднем на 3,4 дня, количество дней с применением обезболивающих средств в месяц — на 12,6 дня.</p></sec><sec><title>Заключение</title><p>Заключение. Необходимо повышение осведомленности терапевтов, неврологов о причинах, закономерностях, методах лечения ЛИГБ, а также о факторах риска ее рецидивирования. Комплаенс пациентов можно повысить путем телефонных интервью, очных консультаций через 1–3 месяца от начала профилактической терапии. При правильном приеме профилактического препарата и соблюдении рекомендаций по ограничению злоупотребления симптоматическими средствами уже через 3 месяца повышается качество жизни пациента, головная боль по частоте и интенсивности уменьшается, улучшаются когнитивные функции.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Study Objective</title><p>Study Objective: The aim of the study was to evaluate the patterns of medical overuse headache (MOH), the effectiveness of therapy, and to compare 2 subgroups of patients with chronic migraine, medical overuse of symptomatic analgesics: with MOH and without MOH.</p></sec><sec><title>Study Design</title><p>Study Design: prospective cohort study.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. The study included 20 patients aged 18 to 75 years with an established diagnosis of chronic migraine medical overuse of symptomatic analgesics. We’re planning to apply a headache diary, several scales about various characteristics of headaches, the psychological state of patients, scales on lifestyle and quality of life, somatic pathology.</p></sec><sec><title>Study Results</title><p>Study Results. All patients were recommended to cancel the “guilty” analgesic and limit the use of the drug with analgesic action from another group. For prophylaxis, metoprolol was used in 6 (30%) cases, topiramate — in 2 (10%) cases, amitriptyline — in 30%, venlafaxine in 30%. After 3 months from the start of therapy, patients noted the greatest reduction in the frequency and intensity of headache when taking amitriptyline at a dose of up to 50 mg, venlafaxine at a dose of up to 150 mg. At the time of withdrawal, “rebound” symptoms and withdrawal syndrome developed in 14 (70%) people. Detoxification therapy (dexamethasone 4–8 mg per 200 ml of saline and magnesia 10% 25 ml N10) was carried out in 12 (60%) patients. Over 3 months of follow-up, the occurrence of a headache attack decreased by 2 points on the intensity scale, duration — by an average of 6 hours, the number of days with a headache increased by an average of 3.4 days, the number of days with the use of pathogens per month — by 12.6 days.</p></sec><sec><title>Conclusion</title><p>Conclusion. It is necessary to raise the awareness of therapists, neurologists about the causes, patterns, methods of treatment of МОН, as well as about the risk factors for its recurrence. Patient compliance can be improved by telephone interviews, face-to-face consultations 1–3 months after the start of preventive therapy. With the correct use of the prophylactic drug and following the recommendations to limit the overuse of symptomatic analgesics, after 3 months the patient's quality of life improves, the headache decreases in frequency and intensity, and cognitive functions improve.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая мигрень</kwd><kwd>лекарственно-индуцированная головная боль</kwd><kwd>хроническая головная боль</kwd><kwd>лекарственный абузус</kwd><kwd>лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic migraine</kwd><kwd>medical overuse headache</kwd><kwd>chronic headache</kwd><kwd>overuse</kwd><kwd>treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Galli F., Tanzilli A., Simonelli A., Tassorelli C. et al. Personality and personality disorders in medication-overuse headache: a controlled study by SWAP-200. Pain Res. Manag. 2019; 2019: 1874078. DOI: 10.1155/2019/1874078</mixed-citation><mixed-citation xml:lang="en">Galli F., Tanzilli A., Simonelli A., Tassorelli C. et al. Personality and personality disorders in medication-overuse headache: a controlled study by SWAP-200. Pain Res. Manag. 2019; 2019: 1874078. DOI: 10.1155/2019/1874078</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Diener H.C., Holle D., Dresler T., Gaul C. Chronic headache due to overuse of analgesics and anti-migraine agents. Dtsch Arztebl. Int. 2018; 115(22): 365–70. DOI: 10.3238/arztebl.2018.0365</mixed-citation><mixed-citation xml:lang="en">Diener H.C., Holle D., Dresler T., Gaul C. Chronic headache due to overuse of analgesics and anti-migraine agents. Dtsch Arztebl. Int. 2018; 115(22): 365–70. DOI: 10.3238/arztebl.2018.0365</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Diener H.C., Dodick D., Evers S., Holle D. et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019; 18(9): 891–902. DOI: 10.1016/S1474-4422(19)30146-2</mixed-citation><mixed-citation xml:lang="en">Diener H.C., Dodick D., Evers S., Holle D. et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019; 18(9): 891–902. DOI: 10.1016/S1474-4422(19)30146-2</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Saper J.R., Da Silva A.N. Medication overuse headache: history, features, prevention and management strategies. CNS Drugs. 2013; 27(11): 867–77. DOI: 10.1007/s40263-013-0081-y</mixed-citation><mixed-citation xml:lang="en">Saper J.R., Da Silva A.N. Medication overuse headache: history, features, prevention and management strategies. CNS Drugs. 2013; 27(11): 867–77. DOI: 10.1007/s40263-013-0081-y</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Табеева Г.Р., Осипова В.В., Филатова Е.Г., Азимова Ю.Э. и др. Диагностика и лечение лекарственно-индуцированной головной боли: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2022; 14(1): 4–13. DOI: 10.14412/2074-2711-2022-1-4-13</mixed-citation><mixed-citation xml:lang="en">Tabeeva G.R., Osipova V.V., Filatova E.G., Azimova Yu.E. et al. Evaluation and treatment of medication-overuse headache: Russian experts’ guidelines. Neurology, Neuropsychiatry, Psychosomatics. 2022; 14(1): 4–13. (in Russian). DOI: 10.14412/2074-2711-2022-1-4-13</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Chen P.-K., Wang S.-J. Medication overuse and medication overuse headache: risk factors, comorbidities, associated burdens and nonpharmacologic and pharmacologic treatment approaches. Curr. Pain Headache Rep. 2019; 23(8): 60. DOI: 10.1007/s11916-019-0796-7</mixed-citation><mixed-citation xml:lang="en">Chen P.-K., Wang S.-J. Medication overuse and medication overuse headache: risk factors, comorbidities, associated burdens and nonpharmacologic and pharmacologic treatment approaches. Curr. Pain Headache Rep. 2019; 23(8): 60. DOI: 10.1007/s11916-019-0796-7</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Katsarava Z., Fritsche G., Muessig M., Diener H.C. et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001; 57(9): 1694–8. DOI: 10.1212/wnl.57.9.1694</mixed-citation><mixed-citation xml:lang="en">Katsarava Z., Fritsche G., Muessig M., Diener H.C. et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001; 57(9): 1694–8. DOI: 10.1212/wnl.57.9.1694</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Katsarava Z., Diener H.C., Limmroth V. Medication overuse headache. focus on analgesics, ergot alkaloids and triptans. Drug Saf. 2001; 24(12): 921–7. DOI: 10.2165/00002018-200124120-00005</mixed-citation><mixed-citation xml:lang="en">Katsarava Z., Diener H.C., Limmroth V. Medication overuse headache. focus on analgesics, ergot alkaloids and triptans. Drug Saf. 2001; 24(12): 921–7. DOI: 10.2165/00002018-200124120-00005</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Radat F., Creac'h C., Guegan-Massardier E., Mick G. et al. Behavioral dependence in patients with medication overuse headache: a cross-sectional study in consulting patients using the DSM-IV criteria. Headache. 2008; 48(7): 1026–36. DOI: 10.1111/j.1526-4610.2007.00999.x</mixed-citation><mixed-citation xml:lang="en">Radat F., Creac'h C., Guegan-Massardier E., Mick G. et al. Behavioral dependence in patients with medication overuse headache: a cross-sectional study in consulting patients using the DSM-IV criteria. Headache. 2008; 48(7): 1026–36. DOI: 10.1111/j.1526-4610.2007.00999.x</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Nielsen M., Carlsen L.N., Munksgaard S.B., Engelstoft I.M.S. et al. Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: a randomized controlled open-label trial. Cephalalgia. 2019; 39(7): 863–72. DOI: 10.1177/0333102419828994</mixed-citation><mixed-citation xml:lang="en">Nielsen M., Carlsen L.N., Munksgaard S.B., Engelstoft I.M.S. et al. Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: a randomized controlled open-label trial. Cephalalgia. 2019; 39(7): 863–72. DOI: 10.1177/0333102419828994</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Carlsen L.N., Munksgaard S.B., Nielsen M., Engelstoft I.M.S. et al. Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. JAMA Neurol. 2020; 77(9): 1069–78. DOI: 10.1001/jamaneurol.2020.1179</mixed-citation><mixed-citation xml:lang="en">Carlsen L.N., Munksgaard S.B., Nielsen M., Engelstoft I.M.S. et al. Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. JAMA Neurol. 2020; 77(9): 1069–78. DOI: 10.1001/jamaneurol.2020.1179</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Grazzi L., Grignani E., D’Amico D., Sansone E. et al. Is Medication overuse drug specific or not? Data from a review of published literature and from an original study on Italian MOH patients. Curr. Pain Headache Rep. 2018; 22(11): 71. DOI: 10.1007/s11916-018-0729-x</mixed-citation><mixed-citation xml:lang="en">Grazzi L., Grignani E., D’Amico D., Sansone E. et al. Is Medication overuse drug specific or not? Data from a review of published literature and from an original study on Italian MOH patients. Curr. Pain Headache Rep. 2018; 22(11): 71. DOI: 10.1007/s11916-018-0729-x</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
